eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
Upcoming Events
There are currently no events scheduled.